Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lara Perryman

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Clinical and Translational Medicine|November 29, 2021
An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategiesAlison Findlay, Craig Turner, Heidi Schilter, et al.
Molecular Cancer Therapeutics|June 11, 2011
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/βAleksandra Bielen, Lara Perryman, Gary M Box, et al.
Journal of Cellular and Molecular Medicine|December 12, 2018
The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosisHeidi Schilter, Alison D Findlay, Lara Perryman, et al.
Iscience|April 17, 2026
Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancerFlorian Laforêts, Panoraia Kotantaki, Samar Elorbany, et al.
Nature|May 29, 2015
The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidaseThomas R Cox, Robin M H Rumney, Erwin M Schoof, et al.
Nature|April 17, 2023
Retraction Note: The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidaseThomas R Cox, Robin M H Rumney, Erwin M Schoof, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2012
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibitionAleksandra Bielen, Gary Box, Lara Perryman, et al.
Plos One|April 15, 2009
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug developmentDorine A Bax, Suzanne E Little, Nathalie Gaspar, et al.
Cell|September 22, 2015
Kinome-wide decoding of network-attacking mutations rewiring cancer signalingPau Creixell, Erwin M Schoof, Craig D Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell linesDorine A Bax, Nathalie Gaspar, Suzanne E Little, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical and Translational Medicine|November 29, 2021
An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategiesAlison Findlay, Craig Turner, Heidi Schilter, et al.
Molecular Cancer Therapeutics|June 11, 2011
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/βAleksandra Bielen, Lara Perryman, Gary M Box, et al.
Journal of Cellular and Molecular Medicine|December 12, 2018
The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosisHeidi Schilter, Alison D Findlay, Lara Perryman, et al.
Iscience|April 17, 2026
Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancerFlorian Laforêts, Panoraia Kotantaki, Samar Elorbany, et al.
Nature|May 29, 2015
The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidaseThomas R Cox, Robin M H Rumney, Erwin M Schoof, et al.
Nature|April 17, 2023
Retraction Note: The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidaseThomas R Cox, Robin M H Rumney, Erwin M Schoof, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2012
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibitionAleksandra Bielen, Gary Box, Lara Perryman, et al.
Plos One|April 15, 2009
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug developmentDorine A Bax, Suzanne E Little, Nathalie Gaspar, et al.
Cell|September 22, 2015
Kinome-wide decoding of network-attacking mutations rewiring cancer signalingPau Creixell, Erwin M Schoof, Craig D Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell linesDorine A Bax, Nathalie Gaspar, Suzanne E Little, et al.
Pageof 3